Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Nevada, Las Vegas, NV 89102, USA.
Int J Mol Sci. 2024 Sep 29;25(19):10511. doi: 10.3390/ijms251910511.
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. SLE is associated with significant complications that substantially increase morbidity and mortality. Given its complex pathogenesis, conventional treatments for SLE often have significant side effects and limited efficacy, necessitating the exploration of novel therapeutic strategies. One promising approach is the use of chimeric antigen receptor (CAR)-T-cell therapy, which has shown remarkable success in treating refractory hematological malignancies. This review provides a comprehensive analysis of the current use of CAR-T-cell therapy in SLE.
系统性红斑狼疮（SLE）是一种复杂的自身免疫性疾病，其特征是产生自身反应性 B 和 T 细胞以及细胞因子，导致慢性炎症影响多个器官。SLE 与显著的并发症相关，这些并发症大大增加了发病率和死亡率。鉴于其复杂的发病机制，SLE 的常规治疗方法往往具有显著的副作用和有限的疗效，因此需要探索新的治疗策略。一种有前途的方法是使用嵌合抗原受体（CAR）-T 细胞疗法，该疗法在治疗难治性血液恶性肿瘤方面已取得显著成功。本综述全面分析了 CAR-T 细胞疗法在 SLE 中的应用。
